{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:09:53Z","timestamp":1786118993836,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1097\/ftd.0b013e318194e484","type":"journal-article","created":{"date-parts":[[2009,1,20]],"date-time":"2009-01-20T03:38:43Z","timestamp":1232422723000},"page":"95-103","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetics of Cyclophosphamide and Thiotepa in a Conventional Fractionated High-Dose Regimen Compared With a Novel Simplified Unfractionated Regimen"],"prefix":"10.1097","volume":"31","author":[{"given":"Corine","family":"Ekhart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd","family":"Rodenhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D R","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210129","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJMoa022794","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.","volume":"349","author":"Rodenhuis","year":"2003","journal-title":"N Engl J Med"},{"key":"R2-11-20210129","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/annonc\/mdl001","article-title":"Efficacy of high-dose alkylating chemotherapy in HER2\/neu-negative breast cancer.","volume":"17","author":"Rodenhuis","year":"2006","journal-title":"Ann Oncol"},{"key":"R3-11-20210129","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.coc.0000093436.16710.e9","article-title":"High-dose chemotherapy and autologous stem cell transplant in women with de novo chemosensitive metastatic breast cancer.","volume":"27","author":"Stemmer","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"R4-11-20210129","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200544110-00003","article-title":"Clinical pharmacokinetics of cyclophosphamide.","volume":"44","author":"de Jonge","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R5-11-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF00685643","article-title":"Dosing of thiotepa for myeloablative therapy.","volume":"37","author":"Przepiorka","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"R6-11-20210129","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1200\/JCO.1997.15.5.1885","article-title":"Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism.","volume":"15","author":"Busse","year":"1997","journal-title":"J Clin Oncol"},{"key":"R7-11-20210129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s002800000132","article-title":"Reduction of cyclophosphamide bioactivation by thiotepa: critical sequence-dependency in high-dose chemotherapy regimens.","volume":"46","author":"Huitema","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"R8-11-20210129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1023\/B:JOPA.0000034405.03895.c2","article-title":"Integrated population pharmacokinetic model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.","volume":"31","author":"de Jonge","year":"2004","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R9-11-20210129","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00001813-200008000-00002","article-title":"The clinical pharmacology of alkylating agents in high-dose chemotherapy.","volume":"11","author":"Huitema","year":"2000","journal-title":"Anticancer Drugs"},{"key":"R10-11-20210129","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/sj.bmt.1703105","article-title":"Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.","volume":"28","author":"Schrama","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"R11-11-20210129","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1023\/A:1026427724108","article-title":"At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies.","volume":"10","author":"Westermann","year":"1999","journal-title":"Ann Oncol"},{"key":"R12-11-20210129","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/sj.bjc.6601001","article-title":"Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): The Netherlands Cancer Institute experience.","volume":"88","author":"Schrama","year":"2003","journal-title":"Br J Cancer"},{"key":"R13-11-20210129","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(98)01350-6","article-title":"Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.","volume":"352","author":"Rodenhuis","year":"1998","journal-title":"Lancet"},{"key":"R14-11-20210129","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1200\/JCO.1996.14.5.1473","article-title":"Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer.","volume":"14","author":"Rodenhuis","year":"1996","journal-title":"J Clin Oncol"},{"key":"R15-11-20210129","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1023\/A:1008328012040","article-title":"A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission.","volume":"10","author":"Rodenhuis","year":"1999","journal-title":"Ann Oncol"},{"key":"R16-11-20210129","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jchromb.2007.04.024","article-title":"Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS\/MS).","volume":"854","author":"Ekhart","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R17-11-20210129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0378-4347(98)00300-4","article-title":"Simultaneous determination of N, N, N-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography.","volume":"716","author":"Huitema","year":"1998","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R18-11-20210129","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","article-title":"Xpose-an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM.","volume":"58","author":"Jonsson","year":"1999","journal-title":"Comput Methods Programs Biomed"},{"key":"R19-11-20210129","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s002800050429","article-title":"A phase I\/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies.","volume":"37","author":"Hussein","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"R20-11-20210129","first-page":"3171","article-title":"Phase I\/pharmacokinetic reevaluation of thioTEPA.","volume":"51","author":"ODwyer","year":"1991","journal-title":"Cancer Res"},{"key":"R21-11-20210129","first-page":"736","article-title":"Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa.","volume":"49","author":"Heideman","year":"1989","journal-title":"Cancer Res"},{"key":"R22-11-20210129","first-page":"1043","article-title":"Pharmacokinetics of continuous-infusion high-dose thiotepa.","volume":"71","author":"Henner","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"R23-11-20210129","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1200\/JCO.1988.6.7.1192","article-title":"Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide.","volume":"6","author":"Ackland","year":"1988","journal-title":"J Clin Oncol"},{"key":"R24-11-20210129","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/BF00688860","article-title":"Pharmacokinetics of thio-TEPA and TEPA in the conventional dose-range and its correlation to myelosuppressive effects.","volume":"27","author":"Hagen","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"R25-11-20210129","first-page":"689","article-title":"High-dose i.v. thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer.","volume":"71","author":"Lazarus","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"R26-11-20210129","first-page":"226","article-title":"Clinical pharmacology of cyclophosphamide.","volume":"33","author":"Bagley","year":"1973","journal-title":"Cancer Res"},{"key":"R27-11-20210129","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF00254204","article-title":"Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma.","volume":"11","author":"Wilkinson","year":"1983","journal-title":"Cancer Chemother Pharmacol"},{"key":"R28-11-20210129","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/1097-0142(197602)37:2<665::AID-CNCR2820370209>3.0.CO;2-D","article-title":"The metabolism of cyclophosphamide. Dose dependency and the effect of long-term treatment with cyclophosphamide.","volume":"37","author":"Mouridsen","year":"1976","journal-title":"Cancer"},{"key":"R29-11-20210129","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1002\/1097-0142(197106)27:6<1512::AID-CNCR2820270636>3.0.CO;2-Q","article-title":"Activation of cyclophosphamide in man and animals.","volume":"27","author":"Brock","year":"1971","journal-title":"Cancer"},{"key":"R30-11-20210129","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF00254056","article-title":"Metabolism of high doses of cyclophosphamide.","volume":"8","author":"Milsted","year":"1982","journal-title":"Cancer Chemother Pharmacol"},{"key":"R31-11-20210129","first-page":"810","article-title":"Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.","volume":"55","author":"Chen","year":"1995","journal-title":"Cancer Res"},{"key":"R32-11-20210129","first-page":"544","article-title":"Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide\/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.","volume":"25","author":"Chen","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"R33-11-20210129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2125.1996.tb00153.x","article-title":"Cyclophosphamide pharmacokinetics in children.","volume":"41","author":"Yule","year":"1996","journal-title":"Br J Clin Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0b013e318194e484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:30:34Z","timestamp":1786037434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-200902000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e318194e484","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}